Eli Lilly Stock Surges on Demand for Weight-Loss Drugs
Related Articles
-
Eli Lilly Stock Surges as Weight Loss Drugs Continue to Fuel Growth
Eli Lilly shares jumped in early trading Tuesday as the drugmaker reported first-quarter earnings above expectations and raised full year...
-
Eli Lilly lifts sales view by $2 billion on soaring weight-loss drug demand
Sky-rocketing demand for Mounjaro and Zepbound, both chemically known as tirzepatide, has propelled the drugmaker's market value above $700 billion - surpassing both Tesla and Walmart. Lilly said its raised forecast reflects "greater clarity about the company's production expansion for the remainder of the year". In the short- to mid-term, the U.S. drugmaker expects sales growth for its weight-loss and diabetes treatments to primarily depend on how much it can produce and ship.
-
Weight-loss drug startup Metsera wants to take on Novo and Lilly. Here's what you need to know
Metsera, a clinical-stage biotechnology startup that develops drugs for obesity and metabolic diseases, launched on Thursday with what it described as a “broad portfolio” of weight-loss treatments that it hopes to bring to market. The company, which has already acquired the U.K.-based startup, Zihipp, and formed a licensing pact with a South Korean drugmaker, D&D Pharmatech, claims that its products could eventually compete with industry leaders Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro....